Market News AIOpen the app

Piper Sandler raised its price target for AbCellera Biologics from $12 to $20 while keeping a buy rating.

OpinionRead the original at moomoo.com
Good for ABCL

Piper Sandler raised its target from $12 to $20 and kept its bullish rating, supporting a more positive view of AbCellera. This is an analyst opinion, not a report of new company results.

ABCL · AbCellera Biologics Inc.

AI read · Good for ABCL

The AI's read

The higher target and unchanged bullish rating show the analyst sees more potential in AbCellera's shares. But the story gives no new sales, trial, or profit results, so this is a positive analyst view, not proof the business has improved.

Get alerts for ABCL

Follow AbCellera Biologics Inc. (ABCL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ABCL
Free on the App Store and Google Play, or on the web.